Abstract
Alemtuzumab Reduces the Rate of Brain Volume Loss in RRMS Patients Over 4 Years Following Switch From SC IFNB-1a: CARE-MS Extension Study (S12.003)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
